Ascentage Pharma
Filed with the SEC on · accession 0001213900-26-116155
AAPG filed a 6-K (foreign company report) with the SEC on Nov 5, 2026. How foreign companies listed in the US report news and events — like an 8-K for them. The stock moved -0.1% by the first close after the filing.
Ascentage Pharma announced it will present data from multiple clinical trials, including an oral presentation of APG-5918, at the ASH Annual Meeting 2026.
Close before
$15.07
Nov 4, 2026
First close after
-0.07%
$15.06
5 trading days
—
Since filing
—
✦ Ask GOAX AI about this filing — what it means for AAPG, what changed since its last filings and what to watch next.
Try it free for 7 days🔔 Want to stay updated on new SEC filings for AAPG?
Click hereAAPG filed a 6-K (SEC filing). Ascentage Pharma announced it will present data from multiple clinical trials, including an oral presentation of APG-5918, at the ASH Annual Meeting 2026.
How foreign companies listed in the US report news and events — like an 8-K for them. Look at the exhibit names: "results", "resign", "notice" tell you the topic. Many 6-Ks are routine (meeting notices); results and leadership changes matter most.
Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A 6-K (foreign company report): How foreign companies listed in the US report news and events — like an 8-K for them.
AAPG closed at $15.07 before the filing and $15.06 on Nov 5, 2026 (-0.07%).
Get alerts when AAPG files with the SEC, plus live charts, key levels and news for 13,000+ stocks.
Try SEPT free for 7 days